Zhongtai: Innovative Drugs lead the market, pay attention to Q1 performance + policy catalysis.

In April, the pharmaceutical Sector is expected to continue its structural market trend, with Innovative Drugs as the main line and thematic opportunities rotating.

Zhitong FinanceApr 2 19:18 ET

SIHUAN PHARM (00460.HK): The injectable polycaprolactone microsphere facial filler independently developed by Meiyan Space has been approved by the National Medical Products Administration.

On April 2, Gelonghui reported that SIHUAN PHARM (00460.HK) announced that its subsidiary, Meiyan Space Biotechnology (Jilin) Co., Ltd., has independently developed an injectable polycaprolactone microsphere facial filler ("this product"), which has officially received the third category medical instruments registration certificate from the National Medical Products Administration of China. This marks a significant breakthrough for SIHUAN PHARM in the medical aesthetics field and injects new vitality into the domestic regenerative medical aesthetics materials market. The injectable polycaprolactone microsphere facial filler, commonly referred to as "girl's needle" in the market, is a regenerative injectable material that stands out in the medical aesthetics market due to its unique mechanism of action. This product is.

Gelonghui FinanceApr 2 07:00 ET

Express News | Sihuan Pharma - Injectable Polycaprolactone Microsphere Facial Filler Obtained Registration Approval From Nmpa

ReutersApr 2 06:57 ET

SIHUAN PHARM rose over 3% in the morning session, and its subsidiary plans to acquire 51% of the shares of Meifu Company for 25.5 million yuan.

Recently, SIHUAN PHARM announced its performance for 2024, with total revenue of approximately 1.901 billion yuan (the same unit as below), an increase of about 2.2% year-on-year.

Sina Hong Kong Stock.Apr 1 23:20 ET

Hong Kong stocks fluctuated | SIHUAN PHARM (00460) rose over 3% again, with the company’s two major Business Sectors of 'medical aesthetics + Innovative Drugs' experiencing rapid growth in 2024.

SIHUAN PHARM (00460) rose more than 3% again, as of the time of writing, up 3.28%, priced at 0.63 HKD, with a turnover of 9.142 million HKD.

Zhitong FinanceApr 1 22:29 ET

The entire pharmaceutical sector has surged sharply; what happened?

On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.

wallstreetcnApr 1 08:38 ET